Non‐invasive fibrosis markers for assessment of liver fibrosis in chronic hepatitis delta
Journal of Viral Hepatitis · 2023
DOI: 10.1111/jvh.13806 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Viral Hepatitis, 2023. Verfasst von Çağdaş Kalkan und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Ankara University Medical School, Ankara, Turkey. Hauptthemen laut MEDLINE: Hepatitis D, Hepatitis D, Chronic, Hepatitis B, Chronic. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 42 Literaturangaben.
Abstract (Originalsprache)
Assessment of liver fibrosis by non‐invasive means is clinically important. Studies in chronic hepatitis delta (CHD) are scarce. We evaluated the performance of eight serum fibrosis markers [fibrosis‐4 score (FIB‐4), aspartate aminotransferase (AST) to alanine aminotransferase (ALT) ratio (AAR), age‐platelet index (API), AST‐to platelet‐ratio‐index (APRI), Goteborg University Cirrhosis Index (GUCI), Lok index, cirrhosis discriminant score (CDS) and Hui score] in CHD and chronic hepatitis B (CHB). Liver stiffness was assessed by transient elastography (TE) in CHD. The ability of fibrosis markers to detect significant fibrosis and cirrhosis were evaluated in 202 CHB and 108 CHD patients using published and new cut‐offs through receiver operating characteristics (ROC) analysis. The latter was also applied to obtain cut‐offs for TE. APRI, Fib‐4, API and Hui score were assessed for significant fibrosis, and APRI, GUCI, Lok index, CDS and AAR for cirrhosis determination. Fibrosis markers displayed weak performance in CHB for significant fibrosis with area under ROC (AUROC) curves between 0.62 and 0.71. They did slightly better for CHD. TE displayed an AUROC of 0.92 and performed better than serum fibrosis markers ( p < 0.05 for fibrosis markers). For cirrhosis determination, CDS and Lok Index displayed an AUROC of 088 and 0.89 in CHB and GUCI, Lok index and APRI displayed AUROCs around 0.90 in CHD. TE displayed the best AUROC (0.95). Hence TE is superior to serum fibrosis markers for diagnosing significant liver fibrosis and cirrhosis. GUCI, Lok index and APRI displayed a reasonable performance in CHD, which needs further confirmation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Ankara University Medical School, Ankara, Turkey.
- Department of Internal Medicine, Ankara University Medical School, Ankara, Turkey.
- Department of Biostatistics, Ankara University Medical School, Ankara, Turkey.
- Department of Pathology, Ankara University Medical School, Ankara, Turkey.
- Hepatology Institute, Ankara University, Ankara, Turkey.
- Department of Gastroenterology & Hepatology, Koç University Medical School, Istanbul, Turkey.
ORCID-Profile: Çağdaş Kalkan, Yusufcan Yılmaz
Zitieren
APA
Kalkan, Ç., Yılmaz, Y., Erdoğan, B. D., Savaş, B., Yurdcu, E., Çalışkan, A., Keskin, O., Gencdal, G., Zeybel, M., Törüner, M., Bozdayi, A. M., Idilman, R., & Yurdaydin, C. (2023). Non‐invasive fibrosis markers for assessment of liver fibrosis in chronic hepatitis delta. Journal of Viral Hepatitis. https://doi.org/10.1111/jvh.13806
Vancouver
Kalkan Ç, Yılmaz Y, Erdoğan BD, Savaş B, Yurdcu E, Çalışkan A, et al. Non‐invasive fibrosis markers for assessment of liver fibrosis in chronic hepatitis delta. Journal of Viral Hepatitis. 2023. doi:10.1111/jvh.13806
BibTeX
@article{Kalkan2023,
author = {Kalkan, Çağdaş and Yılmaz, Yusufcan and Erdoğan, Beyza Doğanay and Savaş, Berna and Yurdcu, Esra and Çalışkan, Aysun and Keskin, Onur and Gencdal, Genco and Zeybel, Müjdat and Törüner, Murat and Bozdayi, A Mithat and Idilman, Ramazan and Yurdaydin, Cihan},
title = {Non‐invasive fibrosis markers for assessment of liver fibrosis in chronic hepatitis delta},
journal = {Journal of Viral Hepatitis},
year = {2023},
doi = {10.1111/jvh.13806}
}
EUVIMED